Role of Interleukin-6 in Type 1 Diabetes Mellitus (Review of Articles) | ||
| Annals of the College of Medicine, Mosul | ||
| Volume 45, Issue 1, June 2023, Pages 92-97 PDF (360.47 K) | ||
| Document Type: Review Paper | ||
| DOI: 10.33899/mmed.2023.137090.1175 | ||
| Author | ||
| Ikram Khazal Qasim Al-Hasso* | ||
| Department of Microbiology, College of Medicine, University of Mosul, Mosul, Iraq | ||
| Abstract | ||
| Type one diabetes mellitus (T1DM) is an autoimmune condition wherein islet cells of pancreas are damaged, necessitating extrinsic insulin therapy for the remainder of life. T1DM affects kids and teenagers and accounts for roughly 5-10% of diabetes cases. Cytokines are low-molecular-weight extracellular molecules that serve as immune modulators which cause β cells impairment in T1DM patients by generating nitric-oxide. Comprehending and controlling autoimmune inflammatory factors, on the contrary, may aid in treating or even avoiding disease advancement. Interleukin-6 (IL-6) is a versatile mediator that have an influential purpose in inflammation besides autoimmune conditions and one of variables implicated in autoimmune inflammation. This cytokine, however, was demonstrated to play a significant function in metabolic control, notably homeostasis of glucose. Objective of this review is to demonstrate the contribution of interleukine-6 in T1DM etiology. | ||
| Keywords | ||
| cytokine; diabetes mellitus; autoimmunity | ||
|
Statistics Article View: 230 PDF Download: 376 |
||